55
A clarification of content in the May article is required. In past articles, I had referenced how past rulings had effectively decriminalized industrial hemp products (source 1; source 2). The DEA recently determined that Industrial Hemp was a Schedule 1 Drug and there is currently a court challenge to the DEA’s perceived ability to effectively add to drug classifications. In my May article, that context was missing when I referenced the legal status of industrial hemp in the USA.
While at Expos and conferences, the two questions I am asked most often with respect to the US Industry are: (1) what companies would I buy stock in “now”; and (2) how do I see the USA’s landscape unfolding given the stronger tone coming out of the current administration with respect to prolonging prohibition.
My answer to the first question is the easier of the two – I do not make stock recommendations and particularly not at expos and conferences. I tend to explain it in terms of Ecoforming and that in turns translates into what I may like today may not be what I like in just a few days’ time and may not be what I disliked just a few days ago. I am very bullish on the industry as a long term overall investment and perhaps even some companies within it but overall one must be prepared to accept that early favorites may fall by the wayside. Companies referenced in articles and those appearing in the various Stock Lists are there as a short list for investors to research further for their own consideration. I cannot repeat enough the value in attending conferences and expos where investors can meet company officials one on one. The number of times that interaction left me with a (correct) feeling one way or another is why I cannot emphasize enough the value in attending.